Drugs / IMV101
last change Dec 2025 re-read 3 minutes ago

IMV101

Developed for
B-cell non-Hodgkin lymphoma
Investigated by
Suzhou Immunofoco Biotechnology Co., Ltd

Trials 1

202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT07376642 Dec 2025 → Dec 2027 expected B-cell non-Hodgkin lymphoma Suzhou Immunofoco Biotechnology Co., Ltd Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as IMV101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07376642 ↗